Where Global Innovation
and Capital Meet
Sectors Art of CVCConsumerEnergyFinancialHealthIndustrialITMediaServicesStartupsTelecomsTransportUniversity

Page 217

PsiQuantum crosses off $450m in funding

M12 returned to reinvest in the quantum computer developer at a valuation topping $3bn, boosting its overall funding to $665m.

Jul 28, 2021

iCapital Network manages to raise $440m

Ping An Global Voyager Fund has returned to back the asset management platform developer’s latest round, at a $4bn valuation.

Jul 28, 2021

Microvast ties up $3bn reverse takeover

Koch Industries and Oshkosh are backing a $540m private placement supporting the merger between advanced battery maker Microvast and a special purpose acquisition company.

Jul 28, 2021

Fireblocks traps $310m in series D round

The digital asset technology provider boosted its valuation to over $2bn in a round co-led by Siam Commercial Bank’s SCB 10X vehicle.

Jul 28, 2021

Landis houses $165m in series A funding

Roc Nation's Arrive unit participated in a debt and equity round that boosted the home rental-to-mortgage service provider's total financing to $182m.

Jul 28, 2021

NGIF closes debut fund

Canadian Gas Association's NGIF Cleantech Ventures has secured almost $40m for the second close of a fund backed by several corporates.

Jul 28, 2021

Herbst leaves Nvidia to set up GFT Ventures

Jeff Herbst has departed from his role heading Nvidia GPU Ventures to join Samsung Ventures alumnus Jay Eum at the recently formed GFT Ventures.

Jul 28, 2021

Nobell tastes $75m in series B round

AgFunder was anong the investors that helped the plant-derived cheese product developer formerly known as Alpine Roads take its total funding past $100m.

Jul 28, 2021

Audax acquires majority stake in Flashpoint

Audax Private Equity has become the Bloomberg and Cisco-backed threat intelligence software provider’s majority shareholder.

Jul 28, 2021

RxCelerate explores corporate venturing

The newly formed RxCapital has made its first investment, in metabolic and cardiovascular disease drug developer Rivus Pharmaceuticals' $35m series A round.

Jul 28, 2021
© 2026 Mawsonia Ltd. All rights reserved.
test reg

Login

Not yet subscribed?

See your subscription offers here